Weil Reps Advent, Avista In $1.5B Spinout Of UCB Pharma Co.
Private equity firms Advent International and Avista Capital Partners, guided by Weil Gotshal & Manges LLP, said Friday they agreed to buy the generic drug unit of Belgium's largest pharmaceutical company...To view the full article, register now.
Already a subscriber? Click here to view full article